BACKGROUND: We assessed risk groups for iron deficiency and the feasibility and efficacy of ferritin testing in a large blood center. STUDY DESIGN AND METHODS: Donors were informed of possible testing in the predonation pamphlet. Plasma ferritin was measured on retention samples (n = 12,595) from representative clinics. Low-ferritin donors (<25 µg/L) were sent a letter and information sheet and not called for 6 months. Ferritin testing was repeated on 25% of donors; donor return rate and frequency were monitored. RESULTS: Low-ferritin donors represented 2.9% of first-time and reactivated (no donation in past 12 months) male donors, 32.2% of first-time and reactivated female donors, 41.6% of repeat male donors, and 65.1% of repeat female donors. A mean of 11.7 months after index donation, the return rate was 76% for normal and 58% for low-ferritin donors; returning low-ferritin donors had made approximately one fewer donation. Ferritin increased by 16.3 and 12.1 µg/L in male and female low-ferritin donors and decreased by 17 µg/L in male and female normal-ferritin donors. CONCLUSION: The minimum hemoglobin level will be increased to 130 g/L for male donors and the minimum interdonation interval changed to 84 days (four donations yearly) for female donors based on iron deficiency risk groups. Large-scale ferritin testing was feasible. Donors informed of low-ferritin results had a lower return rate, donated less often, and had an increase in ferritin on return, approximately 1 year after initial testing, compared to donors with normal ferritin results.
BACKGROUND: We assessed risk groups for iron deficiency and the feasibility and efficacy of ferritin testing in a large blood center. STUDY DESIGN AND METHODS: Donors were informed of possible testing in the predonation pamphlet. Plasma ferritin was measured on retention samples (n = 12,595) from representative clinics. Low-ferritin donors (<25 µg/L) were sent a letter and information sheet and not called for 6 months. Ferritin testing was repeated on 25% of donors; donor return rate and frequency were monitored. RESULTS: Low-ferritin donors represented 2.9% of first-time and reactivated (no donation in past 12 months) male donors, 32.2% of first-time and reactivated female donors, 41.6% of repeat male donors, and 65.1% of repeat female donors. A mean of 11.7 months after index donation, the return rate was 76% for normal and 58% for low-ferritin donors; returning low-ferritin donors had made approximately one fewer donation. Ferritin increased by 16.3 and 12.1 µg/L in male and female low-ferritin donors and decreased by 17 µg/L in male and female normal-ferritin donors. CONCLUSION: The minimum hemoglobin level will be increased to 130 g/L for male donors and the minimum interdonation interval changed to 84 days (four donations yearly) for female donors based on iron deficiency risk groups. Large-scale ferritin testing was feasible. Donors informed of low-ferritin results had a lower return rate, donated less often, and had an increase in ferritin on return, approximately 1 year after initial testing, compared to donors with normal ferritin results.
Authors: Ritchard G Cable; Rebecca J Birch; Bryan R Spencer; David J Wright; Walter Bialkowski; Joseph E Kiss; Jorge Rios; Barbara J Bryant; Alan E Mast Journal: Transfusion Date: 2017-07-13 Impact factor: 3.157
Authors: Eshan U Patel; Jodie L White; Evan M Bloch; Mary K Grabowski; Eric A Gehrie; Parvez M Lokhandwala; Patricia A R Brunker; Ruchika Goel; Beth H Shaz; Paul M Ness; Aaron A R Tobian Journal: Transfusion Date: 2019-02-18 Impact factor: 3.157
Authors: Bryan R Spencer; Yuelong Guo; Ritchard G Cable; Joseph E Kiss; Michael P Busch; Grier P Page; Stacy M Endres-Dighe; Steven Kleinman; Simone A Glynn; Alan E Mast Journal: Transfusion Date: 2019-07-18 Impact factor: 3.157
Authors: Emanuele Di Angelantonio; Simon G Thompson; Stephen Kaptoge; Carmel Moore; Matthew Walker; Jane Armitage; Willem H Ouwehand; David J Roberts; John Danesh Journal: Lancet Date: 2017-09-21 Impact factor: 79.321
Authors: Muriel Lobier; Johanna Castrén; Pia Niittymäki; Elina Palokangas; Jukka Partanen; Mikko Arvas Journal: PLoS One Date: 2019-08-13 Impact factor: 3.240
Authors: Stephen Kaptoge; Emanuele Di Angelantonio; Carmel Moore; Matthew Walker; Jane Armitage; Willem H Ouwehand; David J Roberts; John Danesh; Simon G Thompson Journal: Lancet Haematol Date: 2019-08-02 Impact factor: 30.153